XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue from Contracts with Customers (Tables)
6 Months Ended
Jun. 30, 2023
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2022

$

156,937

$

73,554

$

22,058

Provision related to current period sales

211,709

20,958

73,382

Changes in estimate related to prior period sales

(1,623)

1,230

593

Credits/payments made

(227,167)

(22,509)

(73,076)

Balance at June 30, 2023

$

139,856

$

73,233

$

22,957

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2021

$

142,379

$

54,617

$

13,226

Acquired from BDSI

38,074

18,187

7,575

Provision related to current period sales

233,089

16,675

59,211

Changes in estimate related to prior period sales

(481)

(37)

Credits/payments made

(244,356)

(11,465)

(52,939)

Balance at June 30, 2022

$

168,705

$

78,014

$

27,036

(1)Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Consolidated Balance Sheets.
Schedule of disaggregation of revenue

Three Months Ended June 30,

Six Months Ended June 30,

2023

2022

2023

2022

Belbuca

$

43,136

$

42,301

$

87,348

$

45,611

Xtampza ER

41,245

    

33,190

89,114

64,708

Nucynta IR

28,158

26,554

56,057

55,889

Nucynta ER

19,171

17,077

40,307

36,340

Symproic

3,836

3,860

7,487

4,160

Other

567

592

Total product revenues, net

$

135,546

$

123,549

$

280,313

$

207,300